Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Urinary incontinence

Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Retention, sepsis or acute neurological bladder

Painful retention, anuria with distension, urosepsis, macroscopic haematuria with clots, new saddle anaesthesia or leg weakness, or obstructed infected urinary tract requires urgent decompression and cause treatment.

Action: Use ABCDE and glucose, perform focused abdominal and neurological assessment, measure bladder volume, obtain urine and renal tests, drain when acute retention is confirmed using an appropriate catheter plan, and activate sepsis, urology or spinal pathways.

Synopsis

Classify urinary leakage without dismissing it as ageing, identify retention, infection, neurological and cancer danger, and provide conservative, pharmacological and referral care adapted to cognition, mobility, renal function and personal goals.

  • Classify leakage as urgency, stress, mixed, overflow, continuous or functional by history, diary, examination and residual volume when indicated.
  • First-line assessment asks urgency, exertional leak, frequency, nocturia, stream, emptying, fluid, bowel, mobility, cognition, medicines, pads and goals.
  • Use urine dipstick in women as NICE advises and culture when symptomatic infection or testing criteria apply; do not treat asymptomatic bacteriuria routinely.
  • Measure post-void residual by bladder scan when voiding dysfunction, recurrent infection, neurological disease or overflow is suspected.
  • A three-day bladder diary records time, volume, intake, urgency and leakage and separates small-volume urgency from true polyuria.
  • First-line urgency management is bladder training for at least six weeks, fluid and caffeine adjustment, constipation treatment and mobility-access optimisation.
  • First-line stress or mixed incontinence care includes supervised pelvic-floor muscle training for at least three months, targeted to confirmed contraction ability.
  • In frailty or cognitive impairment, prompted or timed toileting, clear routes, clothing adaptation and carer training may outperform another bladder drug.
  • Before an antimuscarinic, review cognition, constipation, glaucoma risk, emptying and total anticholinergic burden; avoid immediate-release oxybutynin in frail older women.
  • Mirabegron is an option for overactive bladder when antimuscarinics are contraindicated, ineffective or not tolerated, with blood-pressure, interaction, renal and hepatic review.

Key red flags

New urinary retention with saddle sensory loss, bilateral weakness or severe back pain requires emergency cauda equina assessment.

Fever, rigors, hypotension, delirium or flank pain with urinary symptoms requires sepsis and upper-tract obstruction assessment.

Visible haematuria, recurrent unexplained infection, pelvic mass or weight loss requires cancer-appropriate investigation.

Painful palpable bladder, overflow leakage or acute kidney injury requires urgent residual-volume and obstruction assessment.

Continuous leakage after pelvic surgery or radiotherapy can indicate fistula and requires specialist review.

Sudden new incontinence with delirium, marked thirst, hyperglycaemia or medication change should trigger acute reversible-cause assessment.

Overflow pattern

Weak stream, incomplete emptying, dribbling and a high residual indicate voiding failure.

Acute neurological bladder

Retention or incontinence with saddle or bilateral leg signs requires emergency spinal assessment.

Investigation priorities

01
Three-day bladder diaryFirst stepFirst line

Classify storage, volume and timing patterns first line.

Management branches

First-line classificationIdentify subtype and reversible contributors

An older adult reports new or persistent urinary leakage.

  1. Assess urgency, stress, voiding, volume, bowel, medicine, cognition, mobility and red flags and examine relevant systems.
  2. Use bladder diary, urine testing and post-void residual when indicated to distinguish storage, polyuria, infection and emptying failure.
  3. Agree a conservative plan targeted to subtype and function, with containment and skin protection while treatment develops.

Key medicines

Mirabegron prolonged-releaseThe usual adult dose is 50 mg orally once daily, swallowed whole; use 25 mg once daily for specified severe renal or moderate hepatic impairment and follow the current product interaction table.Check blood pressure before and during treatment; avoid severe uncontrolled hypertension, review urinary retention and CYP2D6 interactions, and do not use in end-stage renal or severe hepatic impairment.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG171 urinary incontinence in womenInitial assessment, bladder training, pelvic-floor training and medication considerations.
  • NICE CG97 lower urinary tract symptoms in menRetention, residual measurement, renal risk and male LUTS pathways.
  • NICE CG148 neurological urinary incontinenceAssessment and upper-tract protection in neurological disease.
  • NICE TA290 mirabegronOveractive bladder treatment when antimuscarinics are unsuitable or ineffective.
  • Betmiga UK product informationMirabegron dose, renal and hepatic modification, blood pressure and interactions.
  • NICE NG123 urinary tract infectionCatheter-associated infection and antimicrobial assessment.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom